Peptide Stacks With Tirzepatide

A recurring question on Reddit's r/peptides forum is what supplements or peptides people combine with tirzepatide (sold as Mounjaro for type-2 diabetes and Zepbound for weight management in the US). The combinations mentioned include BPC-157, TB-500, CJC-1295 with ipamorelin, HCG, and various over-the-counter supplements. This article breaks down what the research actually says about each of these compounds, why combining them with tirzepatide raises specific concerns, and where the evidence gaps are.

This is not a protocol guide. If you are considering any combination of peptides, that conversation belongs with a clinician who can review your medical history, current medications, and individual risk profile.

Tirzepatide: what it does and why combinations matter

Tirzepatide is a once-weekly prescription dual GIP and GLP-1 receptor agonist. It is FDA-approved (Mounjaro for type-2 diabetes, Zepbound for chronic weight management) and EMA-authorised (Mounjaro for both indications in the EU). The SURMOUNT-1 trial reported a mean 20.9% body-weight reduction at 72 weeks on the 15 mg dose^[1].

The most pharmacologically relevant feature for anyone considering add-on peptides is delayed gastric emptying. The Mounjaro prescribing information states that tirzepatide "delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications"^[2]. In clinical studies, the first dose reduced peak acetaminophen concentrations by roughly 50% and oral contraceptive component concentrations by 55 to 66%^[2]. This effect is strongest after the initial dose and after each dose escalation, and it diminishes over time.

For injectable peptides (which bypass gastric absorption), delayed emptying is less directly relevant. But tirzepatide's broader metabolic effects and gastrointestinal side effects create a physiological context that no combination protocol has been studied against.

BPC-157 and TB-500: no human trial data, alone or combined

BPC-157 is a 15-amino-acid synthetic pentadecapeptide. The preclinical literature on tissue repair is extensive in rodent models, but a 2025 review in Pharmaceuticals concluded that "a still completely unknown mechanism of action, efficacy, and safety profile cannot be ignored" and noted that no completed human clinical trial has been published^[3]. A Phase I study on 42 healthy volunteers was registered in 2015 and cancelled in 2016 without publishing results^[3].

TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4. Preclinical models show effects on wound healing, angiogenesis, and cardiac repair, but human orthopaedic data are absent. A 2026 review in the American Journal of Sports Medicine stated that "information regarding the indications, dosing, frequency, and duration of treatment remains unknown" for both BPC-157 and TB-500^[4].

Neither peptide has been studied in combination with tirzepatide or any other GLP-1 receptor agonist in any published trial. The U.S. Department of Defense classifies BPC-157 as a prohibited substance, noting "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans"^[5]. Both peptides are WADA-prohibited^[6].

CJC-1295 and ipamorelin: opposing receptor systems

CJC-1295 is a modified growth-hormone-releasing hormone analogue with a half-life of roughly 6 to 8 days^[7]. Ipamorelin is a growth-hormone secretagogue that acts on the ghrelin receptor (GHSR). Neither is approved by the FDA, EMA, or MHRA. No Phase 2 or Phase 3 efficacy trial has been completed for either compound^[4].

The pharmacological concern with combining a ghrelin-receptor agonist (ipamorelin) with a GLP-1 receptor agonist (tirzepatide) is that these receptor systems work in opposite directions on appetite. A 2025 study in Molecular and Cellular Endocrinology demonstrated that "GLP-1R activation produces potent appetite-suppressing effects, whereas GHSR activation strongly stimulates food intake"^[8]. In mice lacking the ghrelin receptor, the GLP-1 agonist liraglutide produced significantly greater appetite suppression than in normal mice, suggesting the two systems actively oppose each other^[8].

Whether this opposition translates to reduced weight-loss efficacy in humans taking both is unknown. No study has examined the combination. But the biological logic for combining a drug that suppresses appetite with a drug that stimulates hunger signalling is, at minimum, worth questioning with a clinician before assuming the two are complementary.

HCG and over-the-counter supplements

The Reddit discussion also mentions HCG (a prescription medication used in fertility and hypogonadism treatment) and several supplements (flaxseed oil, CoQ10, zinc, ashwagandha). HCG is not a grey-market peptide, but combining it with tirzepatide has not been studied. For individuals using both, monitoring by a prescribing physician is essential.

Over-the-counter supplements have more established safety profiles than grey-market peptides, but tirzepatide's delayed gastric emptying may alter absorption timing of oral supplements, particularly fat-soluble ones^[2]. Mention any supplements to your prescriber so they can account for timing and potential interactions.

The grey-market quality problem

A separate risk layer applies to any peptide sourced outside regulated pharmaceutical channels. A 2026 review in Sports Medicine noted that "a parallel 'gray market' of unapproved compounds has emerged, operating largely outside of regulatory oversight" and that "rigorous human safety data are scarce, and there is potential for serious harm to patients"^[9].

When someone combines multiple grey-market peptides with a prescription medication like tirzepatide, the interaction risk is compounded by the basic uncertainty of what is actually in each vial. Independent testing has flagged purity failures, wrong-molecule substitution, and microbial contamination in products sold online.

What we do not know

The evidence gaps are substantial. No published study has examined BPC-157, TB-500, CJC-1295, or ipamorelin in combination with tirzepatide. The dosing protocols for these peptides are themselves unvalidated. Community forums provide signal about what people are trying, but they do not substitute for controlled trials.

The bottom line

Tirzepatide is a prescription medication with a large clinical trial programme behind it^[1]. The peptides commonly discussed as add-ons (BPC-157, TB-500, CJC-1295, ipamorelin) are unapproved, lack human efficacy data, and have never been studied in combination with any GLP-1 receptor agonist^[4][9]. The biological rationale for combining a ghrelin-receptor agonist with a GLP-1 agonist is questionable given their opposing effects on appetite^[8].

If you are using tirzepatide and considering adding other peptides, bring the full list to a prescriber. For regulatory status of each compound, see our peptide pages for tirzepatide, BPC-157, TB-500, CJC-1295, and ipamorelin.

**Medical disclaimer:** This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.